Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | UBE2N | P61088 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014609 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPK1HTTALDH1A1KDM4E | |
| SCHEMBL21390931 | 0.87 | ALDH1A1 (0.62) | SMN1; SMN2MAPK1HTTALDH1A1KDM4E | |
| SCHEMBL1015561 | 0.86 | KDM4E (0.57) | SMN1; SMN2MAPK1HTTALDH1A1KDM4E | |
| SCHEMBL1015559 | 0.86 | KDM4E (0.57) | SMN1; SMN2MAPK1HTTALDH1A1KDM4E | |
| SCHEMBL12954964 | 0.86 | KDM4E (0.57) | SMN1; SMN2MAPK1HTTALDH1A1KDM4E | |
| SCHEMBL13527908 | 0.84 | KDM4E (0.75) | SMN1; SMN2MAPK1HTTALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL31587373 | 0.82 | CCR3 (0.62) | SMN1; SMN2MAPK1HTTALDH1A1KDM4E | |
| SCHEMBL1014458 | 0.81 | CYP11B2 (0.57) | ALDH1A1KDM4EL3MBTL1CYP11B1CYP11B2 | |
| SCHEMBL1014460 | 0.81 | CYP11B2 (0.57) | ALDH1A1KDM4EL3MBTL1CYP11B1CYP11B2 | |
| SCHEMBL13543527 | 0.78 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPK1HTTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089368-B1 | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7652053-B2 | Diaminocycloalkane MCH receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652053-B2 | Diaminocycloalkane MCH receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652053-B2 | Diaminocycloalkane MCH receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-2089368-A1 | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20080146636-A1 | For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol | ERICKSON SHAWN DAVID | 2008-06-19 | — | — | US | disclosed |
| US-20080146636-A1 | For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol | ERICKSON SHAWN DAVID | 2008-06-19 | — | — | US | disclosed |
| US-20080146636-A1 | For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol | ERICKSON SHAWN DAVID | 2008-06-19 | — | — | US | disclosed |
| WO-2008065021-A1 | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008065021-A1 | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146636-A1 | For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol | GPR119, GIPR, EBP | SMN1; SMN2 3793/4885MAPK1 2437/4885HTT 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.